1. Immobilized Recombinant Human IL6 / Interleukin-6 Protein at 2 μg/mL (100 μL/well) can bind Recombinant Human IL6R / CD126 Protein (His Tag) , the EC50 is 8-24 ng/mL.
2. Measured by its ability to enhance the IL6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 20-80 ng/mL.
3. Using the Octet RED System, the affinity constant (Kd) of IL-6R Protein, Human, Recombinant (His Tag) bound Anti-IL6R Antibody was 0.1 nM.
4.Loaded Recombinant Human IL-6R Protein, His Tag on His1K Biosensor, can bind Recombinant Human IL-6 Protein, no Tag with an affinity constant of 0.165 µM as determined in BLI assay(Routinely tested).

IL-6R Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 40 kDa and the accession number is P08887.

Human

HEK293 Cells

interleukin 6 receptor,IL6RQ,IL-6RA,IL6RA,IL-6R-1,IL-6R,IL6Q,gp80,CD126

A DNA sequence encoding the extracellular domain of human IL6R (NP_000556.1) corresponding to amino acid (Met1-Pro365) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Leu 20

≥ 90 % as determined by SDS-PAGE ≥ 95 % as determined by SEC-HPLC.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Interleukin 6 receptor (IL-6R) also known as CD126 (Cluster of Differentiation 126) is a type I cytokine receptor. The low concentration of a soluble form of IL-6 receptor (SIL-6R) acts as an agonist of IL-6 activity. In the IL-6R/CD126/IL6R system, both a membrane-bound IL-6R and a SIL-6R protein can mediate IL-6 signals into the cells through the interaction of gp130. The resulting IL-6/sIL-6R protein complex is also capable of binding to gp130 and inducing intracellular signaling. Through this so-called 'trans-signaling' mechanism, IL-6 can stimulate cells that lack an endogenous mIL-6R. High levels of IL-6 and SIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy